{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Prior to Initiation of Lenalidomide : sCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Prior to Initiation of Lenalidomide : CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Prior to Initiation of Lenalidomide : VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Prior to Initiation of Lenalidomide : PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Year 1 : sCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Year 1 : CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Year 1 : VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Year 1 : PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Number of participants with Best Objective Response of sCR, CR, VGPR, or PR","groups":[{"description":"Participants who received NYESO-1ᶜ²⁵⁹T following ASCT","id":"OG000","title":"NYESO-1ᶜ²⁵⁹T Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received NYESO-1ᶜ²⁵⁹T following ASCT with Best Objective Response (BOR) data.","reportingStatus":"POSTED","timeFrame":"Best Objective Response prior to initiation of lenalidomide and at Year 1","title":"Best Objective Response (BOR)","type":"SECONDARY","unitOfMeasure":"Participants"}